OTTAWA, Sept. 15 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) announced today that it has completed arrangements whereby Dr. Gary K. Schwartz of Memorial Sloan - Kettering Cancer Center (“MSKCC”) in New York City will act as advisor to, and collaborator with, PharmaGap on its drug development program targeting Protein Kinase C (“PKC”) isoforms of therapeutic and clinical interest.
